The Mitochondrial Cascade Hypothesis for Parkinson's Disease

E-ISSN： 1873-4286|17|31|3390-3397

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.31, 2011-10, pp. : 3390-3397

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Mitochondrial Dysfunction in Parkinson's Disease: Implications for Treatment

By Ramsey Chenere P. Giasson Benoit I.

Drugs & Aging, Vol. 24, Iss. 2, 2007-01 ,pp. : 95-105

Adis International

Access to resources Recommend Favorite

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E. Kaheinen P. Penttila K.E. Kaivola J. Linden I.-B.

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Disease Modification in Parkinson's Disease

By Henchcliffe Claire

Drugs & Aging, Vol. 28, Iss. 8, 2011-08 ,pp. : 605-615

Adis International

Access to resources Recommend Favorite

Rivastigmine in Parkinson's disease dementia

By Chitnis Shilpa Rao Jayaraman

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 941-955

Informa Healthcare

Access to resources Recommend Favorite

Nicotinic receptors and Parkinson's disease

By Quik M. Jeyarasasingam G.

European Journal of Pharmacology, Vol. 393, Iss. 1, 2000-03 ,pp. : 223-230

Elsevier

Access to resources Recommend Favorite